Aplastic Anemia
A condition where the body's immune system destroys its own bone marrow, stopping the production of all blood cells and leading to severe fatigue, bleeding, and infections.
Emergency Management: Neutropenic sepsis: Draw blood cultures and start IV Cefepime or Meropenem immediately. Prophylactic platelet transfusions given if count falls below 10,000/mcL to prevent spontaneous brain bleeds.
Aplastic anemia is a rare, life-threatening syndrome of bone marrow failure characterized by peripheral blood pancytopenia (anemia, neutropenia, thrombocytopenia) alongside a markedly hypocellular bone marrow, without evidence of abnormal cellular infiltrates or marrow fibrosis.
Detailed Overview
The disease represents a profound failure of hematopoietic stem cells. In most acquired cases, it is an autoimmune condition where autoreactive T-lymphocytes target and destroy hematopoietic stem and progenitor cells in the bone marrow. This massive destruction leaves the marrow essentially empty, replaced by fat. As a result, the body cannot produce adequate red blood cells to carry oxygen, white blood cells to fight infection, or platelets to stop bleeding. Without intensive treatment such as immunosuppressive therapy or a bone marrow transplant, severe aplastic anemia is rapidly fatal due to overwhelming infection or hemorrhage.
Epidemiology & Demographics
Incidence is rare, roughly 2 cases per million individuals annually in Western countries, with a higher rate in Asia (approx. 7 per million). It has a biphasic age distribution: a peak in young adults (15-25 years) and a second peak in older adults (>60 years).
Etiological Mechanism
Idiopathic (autoimmune) in 65-70% of cases. Secondary causes include drug exposures (chloramphenicol, carbamazepine, NSAIDs), toxic chemicals (benzene), viral infections (seronegative acute hepatitis, EBV, HIV), and radiation.
Primary Causes
Idiopathic immune-mediated stem cell destruction
Drugs (e.g., Chloramphenicol, Carbamazepine, Gold salts)
Toxins (Benzene, insecticides)
Viral infections (Non-A, Non-B, Non-C Hepatitis)
1. An environmental trigger (virus, drug) alters hematopoietic stem cell (HSC) antigens, or there is an intrinsic stem cell defect. 2. A dysregulated immune response occurs, activating cytotoxic CD8+ T-cells. 3. These T-cells expand clonally and migrate to the bone marrow. 4. They secrete massive amounts of inhibitory cytokines, primarily Interferon-gamma (IFN-γ) and Tumor Necrosis Factor-alpha (TNF-α). 5. These cytokines induce apoptosis in HSCs and profoundly inhibit hematopoiesis. 6. The stem cell pool is decimated, and the marrow space fills with adipocytes. The lack of mature cell production results in peripheral pancytopenia.
Diagnostic Criteria & Guidelines
Requires a bone marrow trephine biopsy demonstrating profound hypocellularity (mostly fat spaces) and absence of malignant infiltration or reticulin fibrosis, accompanied by peripheral pancytopenia.
1. Supportive Care: Transfusions (leukodepleted, irradiated packed RBCs and platelets), aggressive management of infections. 2. For patients < 50 years with a matched sibling donor: Allogeneic Hematopoietic Stem Cell Transplant (HSCT) is curative. 3. For patients > 50 years or without a donor: Immunosuppressive Therapy (IST) combining Antithymocyte Globulin (Horse ATG 40 mg/kg IV x 4 days), Cyclosporine 5 mg/kg/day PO (tapered over months), and Eltrombopag (TPO receptor agonist) 150 mg PO daily for 6 months.
Second-Line & Adjunctive Therapy
For patients who fail initial IST: A second course of IST (using Rabbit ATG), Matched Unrelated Donor (MUD) Stem Cell Transplant, or Alemtuzumab.
Surgical & Procedural Management
Bone Marrow Transplantation involves central line placement. No other surgical intervention for the disease itself.
Patient Counseling & Advice
Treatment response to IST is slow, often taking 3-6 months. Patients remain transfusion-dependent during this period. Explain the lifetime risk of evolving into leukemia or PNH.
Follow-Up & Monitoring Schedule
Weekly or biweekly CBC counts. Monthly liver and kidney function tests (monitoring Cyclosporine toxicity). Annual bone marrow biopsy to monitor for clonal evolution to MDS/AML.
Preventive Strategies
Avoid exposure to known myelotoxins (benzene, agricultural pesticides).
Untreated severe aplastic anemia is usually fatal within 6 months. With Matched Sibling HSCT, 5-year survival is >80%. With modern IST + Eltrombopag, response rates are 70-80%, though relapses can occur.